SCHEMBL15219384

SCHEMBL15219384

Cc1cc(C(=O)N2CCOCC2)cc(C(F)(F)F)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 1/20 0.52
EPHX2 P34913 2/20 0.52
MLYCD O95822 1/20 0.51
HPGD P15428 5/20 0.50
POLB P06746 2/20 0.49
CYP3A4 P08684 4/20 0.47
TSHR P16473 3/20 0.47
USP2 O75604 3/20 0.47
CYP2C19 P33261 1/20 0.47
HSD17B10 Q99714 2/20 0.47
ALDH1A1 P00352 2/20 0.47
HTT P42858 2/20 0.47
CASP1 P29466 1/20 0.47
CASP7 P55210 1/20 0.47
CYP2C9 P11712 2/20 0.46
HSP90AA1 P07900 1/20 0.46
HSP90AB1 P08238 1/20 0.46
KDM4E B2RXH2 1/20 0.46
MAPT P10636 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30691979 0.90 HIF1A (0.58) HIF1AEPHX2MLYCDHPGDPOLB
SCHEMBL11916143 0.86 HIF1A (0.56) HIF1AEPHX2MLYCDHPGDPOLB
SCHEMBL6465429 0.85 HPGD (0.68) HPGDTSHRALDH1A1HTTHSP90AA1
SCHEMBL24554590 0.84 EPHX2 (0.53) HIF1AEPHX2MLYCDHPGDPOLB
SCHEMBL427055 0.84 HIF1A (0.64) HIF1AEPHX2HPGDPOLBCYP3A4
SCHEMBL1013250 0.83 EPHX2 (0.52) HIF1AEPHX2MLYCDHPGDPOLB
SCHEMBL12959478 0.83 HIF1A (0.52) HIF1AHPGDPOLBCYP3A4TSHR
SCHEMBL430127 0.83 HIF1A (0.52) HIF1AHPGDPOLBCYP3A4TSHR
SCHEMBL30584223 0.83 EPHX2 (0.52) HIF1AEPHX2MLYCDHPGDPOLB
SCHEMBL11919287 0.82 HPGD (0.49) HIF1AEPHX2MLYCDHPGDPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170218000-A1 PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS ARIAD PHARMACEUTICALS, INC. 2017-08-03 US disclosed
US-9273077-B2 Phosphorus derivatives as kinase inhibitors ARIAD PHARMACEUTICALS, INC. (US) 2016-03-01 US disclosed
US-9012462-B2 Phosphorous derivatives as kinase inhibitors ARIAD PHARMACEUTICALS, INC. (US) 2015-04-21 US disclosed
US-20140364423-A1 Pyrazinopyrazines and Derivatives as Kinase Inhibitors ARIAD PHARMACEUTICALS, INC. 2014-12-11 US disclosed
US-8846664-B2 Pyrazinopyrazines and derivatives as kinase inhibitors ARIAD PHARMACEUTICALS, INC. (US) 2014-09-30 US disclosed
US-20140066406-A1 Phosphorus Derivatives as Kinase Inhibitors ARIAD PHARMACEUTICALS, INC. (US) 2014-03-06 US disclosed
US-20130225528-A1 Phosphorus Derivatives as Kinase Inhibitors ARIAD PHARMACEUTICALS, INC. (US) 2013-08-29 US disclosed
US-20130225527-A1 Phosphorus Derivatives as Kinase Inhibitors ARIAD PHARMACEUTICALS, INC. (US) 2013-08-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140066406-A1 Phosphorus Derivatives as Kinase Inhibitors PHKA1, PIK3CA, PHKA2 HIF1A 2620/4885EPHX2 3793/4885MLYCD 4025/4885
US-20170218000-A1 PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS MAP3K6, PIK3CA, MAP3K20 HIF1A 1732/4885EPHX2 4031/4885MLYCD 4184/4885
US-20140364423-A1 Pyrazinopyrazines and Derivatives as Kinase Inhibitors MAP3K5, MAP3K15, MAP4K2 HIF1A 3399/4885EPHX2 2770/4885MLYCD 2021/4885
US-20130225527-A1 Phosphorus Derivatives as Kinase Inhibitors PHKA1, PIK3CA, PHKA2 HIF1A 2620/4885EPHX2 3793/4885MLYCD 4025/4885
US-20130225528-A1 Phosphorus Derivatives as Kinase Inhibitors PHKA1, PIK3CA, PHKA2 HIF1A 2620/4885EPHX2 3793/4885MLYCD 4025/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.